Paclitaxel is approved in the UK for ovarian, breast and lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma. It is recommended in NICE guidance of June 2001 that it should be used for nonsmall cell lung cancer in patients unsuitable for curative treatment, and in first-line and second-line treatment of ovarian cancer. In September 2001, NICE recommended paclitaxel should be available for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. In 2005, its use in the United States for the treatment of breast, pancreatic, and non-small cell lung cancers was approved by the FDA.
Our company advantages：
Tonda chem-tech co., Ltd is specialized in the field of Pharmaceutical Intermediates. which are widely supplied to many different countries and established suceesfully long-term pharmaceutical coorperation relationship with the biggest superiority as follows:
1. Best quality in your requirement and competitive price in Chna market
2. mature Technical support
3. Professional express delivery
4. Packing as buyer's special request
5. Full experience in export
6. Raw materials from Chinese origin
All we want is win-win business. Send yr. inquiries, you will get it!
China
